-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $7 Price Target

Benzinga·03/26/2025 10:03:51
Listen to the news
HC Wainwright & Co. analyst Emily Bodnar reiterates Atossa Therapeutics (NASDAQ:ATOS) with a Buy and maintains $7 price target.